PARIS and PALO ALTO, Calif., May
6, 2021 /PRNewswire/ -- Sanofi has entered into
a three-year research collaboration with Stanford University School of Medicine. Together,
the two organizations and their scientists will work to advance the
understanding of immunology and inflammation through open
scientific exchange. Additionally, Sanofi will provide funding and
scientific inputs into projects of mutual interest, crossing
multiple therapeutic areas including autoimmune diseases and
inflammatory conditions.
"We look forward to working
with some of the most innovative scientists in the human immunology
community. Together we will explore groundbreaking concepts and
obtain deeper insights into underlying inflammatory disease
mechanisms," said Frank Nestle,
Global Head of Research and Chief Scientific Officer,
Sanofi. "Sanofi's collaboration with
Stanford University aims to transform
how autoimmune disorders and inflammatory conditions are understood
and treated. It will help accelerate our ambitious immunoscience
programs as we advance a rich pipeline of first- and best-in-class
medicines across key therapeutic areas to address unmet patient
needs."
Sanofi and Stanford Medicine will
create a Joint Steering Committee to fund up to three programs a
year. Sanofi will host an annual research forum for researchers
from both organizations to further exchange ideas, share knowledge
and perspectives on relevant scientific matters, and discuss
collaborative research projects.
"Stanford Medicine is dedicated to advancing
knowledge and discovery with the goal of improving our ability to
predict, prevent and cure disease with the most precise
approaches," said Lloyd Minor, MD,
Dean of the Stanford School of Medicine. "The opportunity for
long-term collaboration with our colleagues at Sanofi will allow us
to explore together new frontiers in autoimmune diseases and
inflammatory conditions."
The collaboration will begin with three "deep-dive" research
projects:
- Exploring cytokine crosstalk in type 2 inflammation,
specifically examining the impact of Sanofi's investigational
molecules on excessive type 2 inflammation.
- Decoding molecular drivers of effector and suppressor T cells
in autoimmunity, to better understand the specific antigens that
may cause type 1 diabetes.
- Defining the mechanisms of immune-related adverse events with
immune checkpoint inhibitor therapy – with a focus on pneumonitis
and inflammatory arthritis – to explore the role of genomics and
pathogenic cell identification.
EDITOR'S NOTE: This new initiative is the latest chapter in
Sanofi's long history of collaboration that includes the Sanofi
Innovation Awards (iAwards), a multi-institutional academic
partnership program designed to accelerate and innovative,
early-stage, disease-relevant research towards the clinic. The
iAwards represent one of the largest academic–industry
collaborations run by a biopharma company, and have generated early
research that has led to important scientific advancements in the
field, including contributions to Sanofi's own pipeline.
About Sanofi
Sanofi is dedicated to supporting people through their health
challenges. We are a global biopharmaceutical company focused on
human health. We prevent illness with vaccines, provide innovative
treatments to fight pain and ease suffering. We stand by the few
who suffer from rare diseases and the millions with long-term
chronic conditions.
With more than 100,000 people in 100 countries, Sanofi is
transforming scientific innovation into healthcare solutions around
the globe.
Sanofi, Empowering Life
Sanofi Media
Relations Contact Sally Bain
Tel: +1 781-264-1091
Sally.Bain@sanofi.com
|
Sanofi Investor
Relations Contacts Paris Eva Schaefer-Jansen Arnaud Delepine
Sanofi Investor
Relations Contacts North America Felix Lauscher Fara Berkowitz Suzanne Greco
Sanofi IR main
line: Tel: +33 (0)1 53 77
45 45 investor.relations@sanofi.com
https://www.sanofi.com/en/investors/contact
|
|
|
Sanofi Forward-Looking Statements
This press release contains forward-looking statements as
defined in the Private Securities Litigation Reform Act of 1995, as
amended. Forward-looking statements are statements that are not
historical facts. These statements include projections and
estimates and their underlying assumptions, statements regarding
plans, objectives, intentions and expectations with respect to
future financial results, events, operations, services, product
development and potential, and statements regarding future
performance. Forward-looking statements are generally identified by
the words "expects", "anticipates", "believes", "intends",
"estimates", "plans" and similar expressions. Although Sanofi's
management believes that the expectations reflected in such
forward-looking statements are reasonable, investors are cautioned
that forward-looking information and statements are subject to
various risks and uncertainties, many of which are difficult to
predict and generally beyond the control of Sanofi, that could
cause actual results and developments to differ materially from
those expressed in, or implied or projected by, the forward-looking
information and statements. These risks and uncertainties include
among other things, the uncertainties inherent in research and
development, future clinical data and analysis, including post
marketing, decisions by regulatory authorities, such as the FDA or
the EMA, regarding whether and when to approve any drug, device or
biological application that may be filed for any such product
candidates as well as their decisions regarding labelling and other
matters that could affect the availability or commercial potential
of such product candidates, the fact that product candidates if
approved may not be commercially successful, the future approval
and commercial success of therapeutic alternatives, Sanofi's
ability to benefit from external growth opportunities, to complete
related transactions and/or obtain regulatory clearances, risks
associated with intellectual property and any related pending or
future litigation and the ultimate outcome of such
litigation, trends in exchange rates and prevailing interest
rates, volatile economic and market conditions, cost containment
initiatives and subsequent changes thereto, and the impact that
COVID-19 will have on us, our customers, suppliers, vendors, and
other business partners, and the financial condition of any one of
them, as well as on our employees and on the global economy as a
whole. Any material effect of COVID-19 on any of the
foregoing could also adversely impact us. This situation is
changing rapidly and additional impacts may arise of which we are
not currently aware and may exacerbate other previously identified
risks. The risks and uncertainties also include the uncertainties
discussed or identified in the public filings with the SEC and the
AMF made by Sanofi, including those listed under "Risk Factors" and
"Cautionary Statement Regarding Forward-Looking Statements" in
Sanofi's annual report on Form 20-F for the year ended December 31, 2020. Other than as required by
applicable law, Sanofi does not undertake any obligation to update
or revise any forward-looking information or statements.
Source: Sanofi (EURONEXT: SAN) (NASDAQ: SNY)
View original
content:http://www.prnewswire.com/news-releases/sanofi-establishes-three-year-collaboration-with-stanford-medicine-to-accelerate-immunology-research-301284970.html
SOURCE Sanofi